Therapeutic evaluation of magnetic hyperthermia using Fe3O4-aminosilane-coated iron oxide nanoparticles in glioblastoma animal model

Abstract

Objective: To evaluate the potential of magnetic hyperthermia using aminosilane-coated superparamagnetic iron oxide nanoparticles in glioblastoma tumor model. Methods: The aminosilane-coated superparamagnetic iron oxide nanoparticles were analyzed as to their stability in aqueous medium and their heating potential through specific absorption rate, when submitted to magnetic hyperthermia with different frequencies and intensities of alternating magnetic field. In magnetic hyperthermia in vitro assays, the C6 cells cultured and transduced with luciferase were analyzed by bioluminescence in the absence/presence of alternating magnetic field, and also with and without aminosilane-coated superparamagnetic iron oxide nanoparticles. In the in vivo study, the measurement of bioluminescence was performed 21 days after glioblastoma induction with C6 cells in rats. After 24 hours, the aminosilane-coated superparamagnetic iron oxide nanoparticles were implanted in animals, and magnetic hyperthermia was performed for 40 minutes, using the best conditions of frequency and intensity of alternating magnetic field tested in the in vitro study (the highest specific absorption rate value) and verified the difference of bioluminescence before and after magnetic hyperthermia. Results: The aminosilane-coated superparamagnetic iron oxide nanoparticles were stable, and their heating capacity increased along with higher frequency and intensity of alternating magnetic field. The magnetic hyperthermia application with 874kHz and 200 Gauss of alternating magnetic field determined the best value of specific absorption rate (194.917W/g). When these magnetic hyperthermia parameters were used in in vitro and in vivo analysis, resulted in cell death of 52.0% and 32.8%, respectively, detected by bioluminescence. Conclusion: The magnetic hyperthermia was promissing for the therapeutical process of glioblastoma tumors in animal model, using aminosilane-coated superparamagnetic iron oxide nanoparticles, which presented high specific absorption rate.

Therapeutic Efficiency of Multiple Applications of Magnetic Hyperthermia Technique in Glioblastoma Using Aminosilane Coated Iron Oxide Nanoparticles: In Vitro and In Vivo Study

“…In a previous study developed by our group, we have developed data on stability and hydrodynamic diameter (D H ) distribution of SPIONa dispersed in aqueous solution. These data were generated by dynamic light scattering and demonstrated stability during 24 h of evaluation, without forming agglomerations, mantaining the 100 nm of D H [69]. Similar results were reported by other groups that compared SPIONa with uncoated SPION disperse in aqueous solution and their stability.…”

Comparing the Effects of Intracellular and Extracellular Magnetic Hyperthermia on the Viability of BxPC-3 Cells

“…Upon exposure to 35 mT at 92 kHz for 60 s, the nanoparticles displayed a SAR of 98 W/g Fe in water, corresponding to an ILP of 1.4 nHm 2 /kg (Table 2 and Figure 2). This heating capacity resembles other IONP used for in vitro magnetic hyperthermia in the literature [32][33][34]. Finally, the nanoparticles contained an average of 0.736 ± 0.01 mg of iron for every mg of total nanoparticle.…”

Hadron Therapy, Magnetic Nanoparticles and Hyperthermia: A Promising Combined Tool for Pancreatic Cancer Treatment

“…The patients underwent six semi-weekly hyperthermia sessions for 60 min: after the MNPs injection they were exposed to an alternating magnetic field ( f = 100 kHz, µ 0 H = 2.5~19 mTesla) combined with radiotherapy [ 48 ]. At the preclinical level, for instance MNPs were used for a case of glioblastoma multiforme on Wistar rats, using µ 0 H = 20 mTesla and f = 874 kHz (40 min at T = 42 °C) [ 49 ]. Here, as in many other in-vitro and in-vivo cases, the Brezovich limit is exceeded, thus allowing the release of more thermal energy [ 50 , 51 , 52 ].…”